Chronic Kidney Disease Drugs Market, By Drug Type (Calcium Channel Blockers, Anti-Hypertensive, Anemia Treatment Drugs, ACE Inhibitors, Erythropoiesis-Stimulating Agents, Swell Treatment Drugs, Beta Bloggers, Diuretics and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Channels) – Global Insights, Trends and Forecast, 2017 - 2025

Created On: Jun-2018
Report ID: IR60
Format: PDF

Chronic Kidney Disease Drugs Market: Introduction

Chronic kidney disease, otherwise chronic kidney failures results in the lowering down the function or sometimes failure of kidneys. Wastes and excessive fluids filtered by the kidney are thereby excreted through urine. However, if these fluids reach dangerous levels, wastes and electrolytes are built into the body which may result in the gradual loss of kidney functioning. To retrieve the kidney functioning, numerous drugs are used such as swell treatment drugs, calcium channel bloggers, beta bloggers, and several others. In extreme cases such as kidney failure can be treated by kidney transplantation or artificial filtering. The global chronic kidney disease drugs market is anticipated to grow over a noticeable CAGR over the projected period owing to the rising prevalence of diabetic patients coupled with increasing obesity across the globe.

Market Dynamics

The global chronic kidney disease drugs market size continues to increase at a significant rate, majorly driven by growing number of patients suffering from chronic kidney disease and the rising need for proper treatments in order to improve the quality of life for every patient.

The growing number of elderly populations who are vulnerable to diseases due to poor immunity, such as diabetes, cardiovascular disorders, and neurological conditions, is another major factor behind the growth of this market. According to Insights and Reports, more than 2 million people across the globe are currently receiving treatment with dialysis or kidney transplant in order to stay alive. However, intense competition from several biosimilars and rising number of generic drugs is a major constraint to the global chronic kidney disease drugs market size.

Drug Type

Calcium channel blockers (CCB) segment is anticipated to dominate the global chronic kidney disease drugs market, majorly attributed by the increasing anti-hypertensive capacity in the CCB which aims to protect the renal damage. During the treatment process of chronic kidney diseases, antihypertensive drugs try to maintain the levels of blood pressure in the body. Therefore, the use of CCB may contribute significant growth to the global chronic kidney disease drugs market size over the projected period.

Regional Outlook

In terms of region wise study, North America dominated the global chronic kidney disease drugs market size, followed by Europe. Presence of advanced technology and the strong economic condition has resulted in the dominance of the North America chronic kidney disease drugs market. Concerns regarding the rise in the number of the obese and diabetic population are also expected to boost this regional market in the near future. In addition to this changing healthcare reimbursement environment and an increase in funding by different private organizations government agencies and in the healthcare system is resulting to the rise in the demand for CKD drugs. According to the U.S government health agency, the health spending in the U.S. is expected to rise by 5.3% in 2018 owing to the rising prices of the drugs and other medical goods.

Asia Pacific chronic kidney disease drugs market size will witness the fastest growth rate during the forecast period, owing to the rising number of incidences suffering from diabetes and hypertension. According to the International Diabetes Federation estimates, in India, there were over 72.1 million diabetic patients in India, which is approximately 8.8% of the total population. The rising prevalence of diabetes among the population in this region may further lead to a significant rise in diabetic cases, which in turn might trigger the Asia Pacific chronic kidney disease drugs market share over the projected period.

Competitive Landscape

Global chronic kidney disease drugs market is highly competitive and has numerous numbers of players. Some of the major players in this market include GlaxoSmithKline plc, Johnson & Johnson, Keryx Biopharmaceuticals Co. Ltd., and Pfizer among others. In May 2018, Keryx Biopharmaceuticals Co. Ltd. revealed the trial data of the treatment of CKD with ferric citrate. Data suggested that 76 of 133 patients accomplished nine months of the trial, 30 patients started with renal replacement therapy, 16 patients were terminated, 8 patients received the transplantation whereas 3 patients died during the trials.

Our Research Approach Includes
  •  Market Outlining
  •  Framing discussion guide
  •  Data Validation
  • Data Analysis
  •  Re-Validation and Finalization of Data
  •  Report Insights and Publishing
Our Research Approach Includes
  •  Market Outlining
  •  Framing discussion guide
  •  Data Validation
  • Data Analysis
  •  Re-Validation and Finalization of Data
  •  Report Insights and Publishing
Reach Out to us